Background. Multidrug resistant (MDR) Acinetobacter sp. were deemed a "serious" health threat by the Centers for Disease Control and Prevention with a daunting 63% of infections being nearly untreatable. Underlying this challenging pathogen are the presence of a chromosomal class C β-lactamase, Acinetobacter-derived cephalosporinase (ADC), as well as the abundant prevalence of class D OXA β-lactamases that hydrolyze carbapenems in conjunction with a lack of potent β-lactamase inhibitors. Based on the ability of ETX2514, a rationally designed novel diazabicyclooctane inhibitor ( Figure 1A) , to inhibit class D β-lactamases as well as PBPs, we hypothesized that highly resistant clinical isolates of A. baumannii will demonstrate susceptibility to the sulbactam-ETX2514 combination and that A. baumannii β-lactamases, ADC-7 and OXA-58 will be readily inactivated by ETX2514.
Methods. Susceptibility testing according to Clinical and Laboratory Standards Institute was performed for sulbactam ±4 mg/L ETX2514 using 72 A. baumannii strains. More than half of the isolates are MDR, have ≥ eight resistant determinants, contain an ADC β-lactamase, and have OXA-23 and OXA-58-like β-lactamases in the carbapenem resistant isolates. ADC-7 and OXA-58 β-lactamases were purified and characterized with ETX2514 by steady-state inhibition kinetics and Q-TOF mass spectrometry.
Results. The A. baumannii strains demonstrated an MIC 90 of 32 mg/L for sulbactam and 2 mg/L for the sulbactam-ETX-2514 combination. The addition of ETX2514 lowered the MIC 50 from 8 to 1 mg/L ( Figure 1B ). ETX-2514 effectively inhibited purified OXA-58 (k 2 /K = 2.5 ± 0.3 × 10 5 M −1 s −1 and K i apP = 0.39 ± 0.01 µM) and ADC-7 (k 2 /K =1.0 ± 0.1 × 10 6 M −1 s −1 and K i app = 0.11 ± 0.04 µM). The two β-lactamases displayed similar dissociation constants (K d =1 ± 0.1 nM), but ADC-7 possessed a faster dissociation rate (k off =8 ± 1 × 10 −4 s −1 for ADC-7 and 1.6 ± 0.3 × 10 −4 s −1
for OXA-58). Using mass spectrometry, ADC-7 and OXA-58 were found to stably bind the ETX-2514 compound for up to 24 hours ( Figure 1C) .
Conclusion. ETX2514 is a new β-lactamase inhibitor that is strikingly effective at restoring susceptibility to highly drug-resistant A. baumannii isolates when combined with sulbactam via inhibition of the ADC-7 and OXA-58 β-lactamases. Background. Ceftobiprole medocaril (prodrug of ceftobiprole) is an advanced cephalosporin, approved for adults in multiple European countries for the treatment of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) or community-acquired pneumonia. It is not approved in the US; however, it has achieved qualified infectious disease product status and two phase 3 studies supported by BARDA are planned to begin in the US in 2017. Results. Methicillin-resistant S. aureus (MRSA) S rates were lower than for methicillin-susceptible S. aureus (MSSA) for most agents. For levofloxacin (LEV) and erythromycin (ERY), the S rates were LEV: MRSA, 23.2%; MSSA, 86.1%; ERY: MRSA, 9.0%; MSSA, 69.3%. All MSSA and 99.0% of MRSA were S to ceftobiprole, while all MSSA and 96.5% of MRSA were S to ceftaroline (CPT). For CoNS, 98.1% of ceftobiprole MIC values were ≤2mg/L. Ceftobiprole was active against Enterococcus faecalis (96.1% ≤2mg/L) and not against E. faecium (18.9% ≤2mg/L). Against ENT, ceftobiprole (85.0%S) was similar in activity to ceftazidime (CAZ, 87.2%S) and cefepime (FEP, 88.9%S). The MIC 50/90 values for ceftobiprole, FEP, and CAZ against PSA were identical at 2/16 mg/L.
Conclusion. Ceftobiprole exhibited potent in vitro activity against GP and GN isolates from contemporary BSI in the US. These results support further clinical evaluation of ceftobiprole for the treatment of BSI.
